No Data
Indaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source Summit
Maxim Group Maintains Indaptus Therapeutics(INDP.US) With Buy Rating, Maintains Target Price $10
Maxim Group Maintains Indaptus Therapeutics(INDP.US) With Buy Rating, Cuts Target Price to $10
Analysts Have Conflicting Sentiments on These Healthcare Companies: Indaptus Therapeutics (INDP) and Fate Therapeutics (FATE)
Indaptus Therapeutics Reports Q3 2025 Financial Results and Corporate Update
Express News | Indaptus Therapeutics Q3 EPS $(2.98) Beats $(4.17) Estimate
Towen : holding for a big pop or even a slow climb wish I'd seen the bottom but I think it's up from here